ARCHIVES

Bezwoda’s ’95 Phase II Study Entirely A Sham, Audit Finds.

This article is from The Cancer Letter archive.

Vol. 27 No. 17 | April 27, 2001

Download PDF Visit The Full Archive

Related Articles

Are Lab Budgets Excessive? Views On Intramural Program

April 21, 1995

Drug Approvals: FDA Grants Accelerated Approval to Imbruvica

November 15, 2013

Funding opportunities listed.

March 12, 2004

Boyd Steps Down As DTP Director, Returns to Research

February 16, 1990

Five Investigations Probe NIH Radiation Contamination

November 17, 1995

Cancer Program Advocates, Success Overcame Powerful Negative Factors To Win Budget Fight

August 10, 1979